Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05647343 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers
A Phase 1 study of Adverse Effect of Drugs and Medicaments in Therapeutic Use, sponsored by Atlas Molecular Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT05647343 is a Phase 1 study of Adverse Effect of Drugs and Medicaments in Therapeutic Use that has completed, run by Atlas Molecular Pharma. The registered enrollment target is 42 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05647343, a Phase 1 study of Adverse Effect of Drugs and Medicaments in Therapeutic Use, has completed, sponsored by Atlas Molecular Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess the safety, tolerability and pharmacokinetics of ATL-001 (ciclopirox olamine) in healthy volunteers
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ciclopirox Olamine Oral
Study Locations (1)
New Jersey
- Hassman Research Institute, LLC - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2024-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05647343
The ClinicalTrials.gov registry entry for NCT05647343 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atlas Molecular Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adverse Effect of Drugs and Medicaments in Therapeutic Use appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05647343 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05647343 about?
NCT05647343 is a clinical study titled "Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers". The goal of this clinical trial is to assess the safety, tolerability and pharmacokinetics of ATL-001 (ciclopirox olamine) in healthy volunteers
What is the current status of trial NCT05647343?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-03-31. Estimated completion is 2024-04-08.
What conditions does trial NCT05647343 study?
This clinical trial studies the following conditions: Adverse Effect of Drugs and Medicaments in Therapeutic Use.
What interventions are being tested in trial NCT05647343?
The interventions under investigation include: Placebo (OTHER), Ciclopirox Olamine Oral (DRUG).
Who is sponsoring clinical trial NCT05647343?
This trial is sponsored by Atlas Molecular Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05647343 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.